Alkermes (ALKS) Issues FY18 Earnings Guidance

Alkermes (NASDAQ:ALKS) issued an update on its FY18 earnings guidance on Wednesday morning. The company provided earnings per share guidance of ($0.23-0.03) for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.73. The company issued revenue guidance of $975 million-1.025 billion, compared to the consensus revenue estimate of $1.01 billion.

Alkermes (NASDAQ ALKS) opened at $54.69 on Wednesday. Alkermes has a twelve month low of $46.42 and a twelve month high of $64.04. The company has a market capitalization of $8,513.03, a price-to-earnings ratio of -49.27 and a beta of 1.94. The company has a quick ratio of 2.72, a current ratio of 3.05 and a debt-to-equity ratio of 0.23.

Alkermes (NASDAQ:ALKS) last announced its earnings results on Wednesday, February 14th. The company reported $0.31 EPS for the quarter, topping the Zacks’ consensus estimate of $0.13 by $0.18. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. The company had revenue of $275.37 million for the quarter, compared to analysts’ expectations of $251.23 million. During the same period last year, the firm earned $0.02 EPS. Alkermes’s revenue for the quarter was up 29.0% compared to the same quarter last year. analysts anticipate that Alkermes will post -0.59 earnings per share for the current year.

A number of equities analysts recently commented on ALKS shares. Credit Suisse Group set a $66.00 target price on Alkermes and gave the stock a buy rating in a report on Tuesday, November 28th. JPMorgan Chase & Co. set a $78.00 target price on Alkermes and gave the stock a buy rating in a report on Friday, October 27th. Zacks Investment Research raised Alkermes from a hold rating to a buy rating and set a $61.00 price target on the stock in a report on Monday, January 8th. Mizuho set a $81.00 price target on Alkermes and gave the company a buy rating in a report on Saturday, October 21st. Finally, BidaskClub raised Alkermes from a sell rating to a hold rating in a report on Friday, January 26th. Eight investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $64.17.

In other news, SVP Laurie Keating sold 6,249 shares of the firm’s stock in a transaction dated Wednesday, December 20th. The stock was sold at an average price of $121.20, for a total transaction of $757,378.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Shane Cooke sold 6,207 shares of the firm’s stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $60.22, for a total value of $373,785.54. Following the transaction, the insider now owns 80,915 shares of the company’s stock, valued at approximately $4,872,701.30. The disclosure for this sale can be found here. Over the last three months, insiders have sold 135,485 shares of company stock worth $8,227,502. Insiders own 5.34% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Alkermes (ALKS) Issues FY18 Earnings Guidance” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Earnings History and Estimates for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with's FREE daily email newsletter.

Leave a Reply